A Study of Avutometinib for People With Solid Tumor Cancers

Status Recruiting

Clinical Trial Summary

The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Brain Neoplasms
Central Nervous System Neoplasms
Central Nervous System Tumor
CNS Tumor, Adult
CNS Tumor, Childhood
CNS Tumors
Glioma
Low-grade Glioma
Neoplasms
Nervous System Neoplasms
Neuroblastoma
Neurofibroma
Neurofibroma, Plexiform
Neurofibromatoses
NF1
Optic Pathway Gliomas
Plexiform Neurofibroma
Primary Brain Tumor
Refractory Cancer
Solid Carcinoma
Solid Tumor
Solid Tumor, Adult

Clinical Trial Details

NCT number	NCT06104488
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact	Sameer Farouk Sait, MD
Phone	212-639-3449
Email	faroukss@mskcc.org
Status	Recruiting
Phase	Phase 1
Start date	October 20, 2023
Completion date	October 20, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05580991` - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors	Phase 1
Recruiting	`NCT05691608` - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2	N/A
Active, not recruiting	`NCT02846038` - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting	`NCT05159388` - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors	Phase 1/Phase 2
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Recruiting	`NCT06014502` - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors	Phase 1
Recruiting	`NCT05981703` - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors	Phase 1
Recruiting	`NCT04107311` - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting	`NCT04078152` - Durvalumab Long-Term Safety and Efficacy Study	Phase 4
Completed	`NCT02250157` - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies	Phase 1
Recruiting	`NCT05566574` - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer	Phase 1/Phase 2
Recruiting	`NCT03943004` - Trial of DFP-14927 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT06036836` - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)	Phase 2
Recruiting	`NCT05798546` - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)	Phase 1
Recruiting	`NCT05525858` - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated	`NCT04586335` - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.	Phase 1
Active, not recruiting	`NCT00479128` - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors	Phase 1
Recruiting	`NCT04143789` - Evaluation of AP-002 in Patients With Solid Tumors	Phase 1/Phase 2
Not yet recruiting	`NCT04550663` - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2